secwatch.observer — SEC 8-K summary
======================================

Issuer:     SYNLOGIC, INC. (SYBX)
CIK:        0001527599
Form:       8-K
Filed at:   2022-12-15T23:59:59+00:00
Accession:  0001193125-22-305412
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synlogic reports SYNB8802 Phase 1b proof of concept: -38% urinary oxalate reduction in enteric hyperoxaluria
--------------------------------------------------------------------------------

- SYNB8802 reduced urinary oxalate by 38% vs placebo at 3x10^11 TID dose in Roux-en-Y gastric bypass patients.
- No serious adverse events; GI AEs mild and similar in frequency between active and placebo groups.
- Third positive clinical readout for Synlogic in 2022, following SYNB1934 for PKU and SYNB1353 for homocystinuria.
- Company to host webcast today at 8:30 AM ET with Dr. Kyle Wood of UAB.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527599/000119312522305412/0001193125-22-305412-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527599/000119312522305412/d426522d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-305412

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer